Contact

Bright Basin 95 Home About Services Research Overview Risks & Safety Who Was Studied Contact Evidence, uncertainty & safety Ibogaine And PTSD: What The Research Shows A calm, evidence-first look at early findings, real risks, legal limits, and the questions that remain around an unapproved psychedelic approach. Early signals are not the same as established care. The strongest question is not whether a story sounds compelling, but what evidence, screening, and follow-up can support. Post-traumatic stress disorder is serious, common, and often persistent. The National Institute of Mental Health’s PTSD statistics place lifetime U.S. prevalence near 6% of adults. Intrusive thoughts, avoidance, negative mood, and hyperarousal can affect work, relationships, sleep, and psychological well-being. Ibogaine and ptsd are being discussed together because some trauma patients report rapid changes after ibogaine treatment. Those reports deserve careful attention, but they do not settle questions about safety, efficacy, or long-term outcomes. Context matters Understanding PTSD: a brief overview Post-traumatic stress disorder can follow traumatic experiences such as combat, assault, accidents, disaster, or repeated exposure to threat. PTSD symptoms are not simply a failure to “move on”; they reflect patterns of distress, memory, arousal, and avoidance that can become entrenched in the central nervous system. Standard care includes trauma-focused psychotherapy, cognitive behavioral therapy, and eye movement desensitization and reprocessing, alongside pharmacotherapy such as selective serotonin reuptake inhibitors. The Department of Veterans Affairs overview of PTSD care describes the role of evidence-based treatment and the importance of a qualified clinical assessment. Traditional treatments help many people, yet only about half of people with post-traumatic stress disorder achieve full remission with first-line approaches. That gap explains interest in psychedelic medicine

A place for careful feedback